Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria

Richard J. Kelly, Matthew Holt, Jennifer Vidler, Louise M. Arnold, Joanna Large, Briony Forrest, Catherine Barnfield, Alexandra Pike, Morag Griffin, Talha Munir, Petra Muus, Sateesh K. Nagumantry, Abraham Varghese, John R. Davies, Roochi Trikha, Austin G. Kulasekararaj, Lindsay Mitchell, Shreyans Gandhi

Blood (2024) 143 (12): 1157–1166.

https://doi.org/10.1182/blood.2023021762

Published: 2024

Journal Articles

Treatment Outcomes of Complement Protein C5 Inhibition in 509 Patients with Paroxysmal Nocturnal Hemoglobinuria in the United Kingdom

Richard Kelly, Matthew Holt, Jennifer Vidler, Louise Arnold, Joanna Large, Briony Forrest, Catherine Barnfield, Alexandra Pike, Morag Griffin, Talha Munir, Petra Muus, Sateesh K. Nagumantry, Roochi Trikha, Austin Kulasekararaj, Lindsay Mitchell, Shreyans Ghandi

Blood (2022) 140 (Supplement 1): 5792–5794.

https://doi.org/10.1182/blood-2022-167725

Published: 2022

Journal Articles

Pharmacologic Co-Blockade of IFNγR and IL6R Pathways to Prevent and Treat GvHD

Jaebok Choi, PhD, Matthew L Cooper, PhD, Kiran R. Vij, MD, Bing Wang, Julie Ritchey, Bader Alahmari, MD, Matthew Holt, John F DiPersio, MD PhD

Blood (2016) 128 (22): 3353.

https://doi.org/10.1182/blood.V128.22.3353.3353

Published: 2016

Journal Articles

Expansion and Maintenance of Hematopoietic Stem and Progenitor Cells in Course of Long-Term Inhibition of CXCR4/CXCL12 Signaling

Darja Karpova, PhD, Julie Ritchey, Matthew Holt, Darlene Monlish, PhD, Laura G. Schuettpelz, MD PhD, Wei Yang, Jean-Pierre Levesque, PhD, Allison Robyn Pettit, PhD BSc, Michael P. Rettig, PhD, Halvard Bonig, MD MA, John F DiPersio, MD PhD

Blood (2016) 128 (22): 2648.

https://doi.org/10.1182/blood.V128.22.2648.2648

Published: 2016

Journal Articles

Ex Vivo Evaluation of VLA-4 Expression in Primary Human Multiple Myeloma Bone Marrow Samples and In Vivo Mobilization of Murine Multiple Myeloma Cells with Small Molecule VLA-4 Inhibitors

Chantiya Chanswangphuwana, MD, Michael P. Rettig, PhD, Walter Akers, Deep Hathi, Matthew Holt, Julie O'Neal, PhD, Julie Ritchey, Danny Kohnen, Justin A King, Michael H. Tomasson, MD, Ravi Vij, MD, Monica Shokeen, PhD, John F DiPersio, MD PhD

Blood (2016) 128 (22): 2056.

https://doi.org/10.1182/blood.V128.22.2056.2056

Published: 2016

Journal Articles

Combined Targeting of CXCR2 and VLA4 Results in Rapid and Synergistic Mobilization of Hematopoietic Stem and Progenitor Cells in Mice

Darja Karpova, PhD, Michael P. Rettig, PhD, Linda Eissenberg, PhD, Julie Ritchey, Matthew Holt, Richard Heier, Stacy Arnett, PhD, Marvin Meyers, PhD, David W. Griggs, PhD, Peter Ruminski, PhD, Dwight Morrow, PhD, John F DiPersio, MD PhD

Blood (2016) 128 (22): 659.

https://doi.org/10.1182/blood.V128.22.659.659

Published: 2016

Journal Articles

Ixazomib, an Oral Proteasome Inhibitor, Induces Rapid Mobilization of Hematopoietic Stem Cells in Mice

Armin Ghobadi, MD, Michael P. Rettig, PhD, Matthew Holt, Julie Ritchey, Linda Eissenberg, John F. DiPersio, MD PhD

Blood (2015) 126 (23): 513.

https://doi.org/10.1182/blood.V126.23.513.513

Published: 2015

Journal Articles

A Phase I/II Trial of Intravenous Azacitidine for Acute Gvhd Prophylaxis in Patients Undergoing Matched Unrelated Stem Cell Transplantation: Phase I Results

Mark A. Schroeder, MD, Jaebok Choi, PhD, Matthew L Cooper, PhD, David Schwab, BA CCRP, Sarah Willey, Jingxia (Esther) Liu, PhD, Matthew Holt, Linda Eissenberg, Iskra Pusic, MD, Armin Ghobadi, MD, Rizwan Romee, MD, John S. Welch, MD PhD, Keith Stockerl-Goldstein, MD, Camille N. Abboud, MD FACP, Ravi Vij, MD, Geoffrey L. Uy, MD, Peter Westervelt, MD PhD, John F Dipersio, MD PhD

Blood (2015) 126 (23): 1935.

https://doi.org/10.1182/blood.V126.23.1935.1935

Published: 2015

Journal Articles

Preclinical Studies of the IAP Antagonist Debio 1143 in Combination with Cytarabine or Doxorubicin in a Mouse Model of AML

Ambrose Campbell, Ezhilarasi Chendamarai, PhD, Matthew Holt, Julie Prior, Linda Eissenberg, PhD, Michael P. Rettig, PhD, Gregoire Vuagniaux, PhD, Claudio Zanna, PhD, John F. DiPersio, MD PhD

Blood (2014) 124 (21): 5296.

https://doi.org/10.1182/blood.V124.21.5296.5296

Published: 2014

Journal Articles

ALT-1188: A New CXCR4 Antagonist In Development For Mobilization Of HSPCs

Michael P. Rettig, PhD, Armin Ghobadi, MD, Matthew Holt, Stephanie Meier, Julie Ritchey, Yesim Tahirovic, PhD, Alexander Bridges, PhD, Doug Gooding, PhD, John F. Dipersio, MD, PhD

Blood (2013) 122 (21): 891.

https://doi.org/10.1182/blood.V122.21.891.891

Published: 2013

Journal Articles

Inhibition Of Nuclear Transport Modulator Xpo1/CRM1 For The Treatment Of Acute Myeloid Leukemia (AML)

Michael P. Rettig, PhD, Matthew Holt, Julie Prior, Sharon Shacham, PhD, MBA, Michael Kauffman, MD, PhD, Dilara McCauley, PhD, John F. Dipersio, MD, PhD

Blood (2013) 122 (21): 237.

https://doi.org/10.1182/blood.V122.21.237.237

Published: 2013

Journal Articles

Bortezomib Can Overcome Stroma-Mediated Chemotherapy Resistance in Acute Lymphoblastic Leukemia.

Ibraheem H. Motabi, MD, Julie Ritchey, Matthew Holt, John F. DiPersio, MD, PhD

Blood (2012) 120 (21): 2475.

https://doi.org/10.1182/blood.V120.21.2475.2475

Published: 2012

Journal Articles

The Effect of Bortezomib (B) Alone or in Combination with Other Agents for Stem Cell Mobilization in Mice

Armin Ghobadi, MD, Matthew Holt, Julie Ritchey, John F. DiPersio, MD, PhD

Blood (2012) 120 (21): 583.

https://doi.org/10.1182/blood.V120.21.583.583

Published: 2012

Journal Articles

In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia

Jaebok Choi, Julie Ritchey, Julie L. Prior, Matthew Holt, William D. Shannon, Elena Deych, David R. Piwnica-Worms, John F. DiPersio

Blood (2010) 116 (1): 129–139.

https://doi.org/10.1182/blood-2009-12-257253

Published: 2010

Includes: Supplemental data

Journal Articles

Pegylated Recombinant Murine GM-CSF Is a Potent Mobilizer of Murine Bone Marrow Progenitors, Synergizes with BIO5192 and Plerixafor (AMD3100), and Skews Mobilized Cells to a Tolerogenic Phenotype.

Mark A. Schroeder, MD, Jonathan D. Ricks, Jaebok Choi, Ph.D., Julie Ritchey, Matthew Holt, Brian K. Dieckgraefe, M.D./Ph.D., John F. DiPersio, MD, PhD

Blood (2009) 114 (22): 2432.

https://doi.org/10.1182/blood.V114.22.2432.2432

Published: 2009

Journal Articles

Preferential Mobilization of CD34+ Plasmacytoid Dendritic Cell Precursors by Plerixafor.

Michael P. Rettig, PhD, Kyle McFarland, Julie Ritchey, Matthew Holt, Elena Deych, PhD, Sandra Lopez, Jeremy Gabriel, Stephanie L Bauer, FNP, Amanda F Cashen, MD, John F. DiPersio, MD, PhD

Blood (2009) 114 (22): 32.

https://doi.org/10.1182/blood.V114.22.32.32

Published: 2009

Journal Articles

Rapid Mobilization of Long Term Repopulating Hematopoietic Stem Cells (HSC) with AMD15057, a Small Molecule Inhibitor of VLA4; Synergism with AMD3100 and G-CSF

Pablo A. Ramirez, MD, Michael Rettig, PhD, Matthew Holt, Julie Ritchey, John F. DiPersio, MD, PhD

Blood (2008) 112 (11): 615.

https://doi.org/10.1182/blood.V112.11.615.615

Published: 2008

Journal Articles

Characterization of Human CD34+ Hematopoietic Stem Cells Following Administration of G-CSF or Plerixafor

Michael P. Rettig, PhD, William D. Shannon, PhD, Julie Ritchey, Matthew Holt, Kyle McFarland, Sandra Lopez, Jeremy Gabriel, John F. DiPersio, MD, PhD

Blood (2008) 112 (11): 3476.

https://doi.org/10.1182/blood.V112.11.3476.3476

Published: 2008

Journal Articles

Mobilization of Normal Mouse Progenitors and Acute Promyelocytic Leukemia (APL) Cells with Inhibitors of CXCR4 and VLA-4 in Splenectomized and Unsplenectomized Mice.

Pablo A. Ramirez, MD, Matthew Holt, Michael P. Rettig, PhD, Julie Ritchey, John F. DiPersio, MD, PhD

Blood (2007) 110 (11): 2219.

https://doi.org/10.1182/blood.V110.11.2219.2219

Published: 2007

Journal Articles

M2-10B4 Mesenchymal Stromal Cells Confer an In Vitro Protective Effect of Murine mCGPR/+ Acute Promyelocytic Leukemic Cells Against Chemotherapy.

Pablo A. Ramirez, MD, Michael P. Rettig, PhD, Matthew Holt, John F. DiPersio, MD, PhD

Blood (2007) 110 (11): 2844.

https://doi.org/10.1182/blood.V110.11.2844.2844

Published: 2007

NARROW

Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria

Treatment Outcomes of Complement Protein C5 Inhibition in 509 Patients with Paroxysmal Nocturnal Hemoglobinuria in the United Kingdom

Pharmacologic Co-Blockade of IFNγR and IL6R Pathways to Prevent and Treat GvHD

Expansion and Maintenance of Hematopoietic Stem and Progenitor Cells in Course of Long-Term Inhibition of CXCR4/CXCL12 Signaling

Ex Vivo Evaluation of VLA-4 Expression in Primary Human Multiple Myeloma Bone Marrow Samples and In Vivo Mobilization of Murine Multiple Myeloma Cells with Small Molecule VLA-4 Inhibitors

Combined Targeting of CXCR2 and VLA4 Results in Rapid and Synergistic Mobilization of Hematopoietic Stem and Progenitor Cells in Mice

Ixazomib, an Oral Proteasome Inhibitor, Induces Rapid Mobilization of Hematopoietic Stem Cells in Mice

A Phase I/II Trial of Intravenous Azacitidine for Acute Gvhd Prophylaxis in Patients Undergoing Matched Unrelated Stem Cell Transplantation: Phase I Results

Preclinical Studies of the IAP Antagonist Debio 1143 in Combination with Cytarabine or Doxorubicin in a Mouse Model of AML

ALT-1188: A New CXCR4 Antagonist In Development For Mobilization Of HSPCs

Inhibition Of Nuclear Transport Modulator Xpo1/CRM1 For The Treatment Of Acute Myeloid Leukemia (AML)

Bortezomib Can Overcome Stroma-Mediated Chemotherapy Resistance in Acute Lymphoblastic Leukemia.

The Effect of Bortezomib (B) Alone or in Combination with Other Agents for Stem Cell Mobilization in Mice

In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia

Pegylated Recombinant Murine GM-CSF Is a Potent Mobilizer of Murine Bone Marrow Progenitors, Synergizes with BIO5192 and Plerixafor (AMD3100), and Skews Mobilized Cells to a Tolerogenic Phenotype.

Preferential Mobilization of CD34+ Plasmacytoid Dendritic Cell Precursors by Plerixafor.

Rapid Mobilization of Long Term Repopulating Hematopoietic Stem Cells (HSC) with AMD15057, a Small Molecule Inhibitor of VLA4; Synergism with AMD3100 and G-CSF

Characterization of Human CD34+ Hematopoietic Stem Cells Following Administration of G-CSF or Plerixafor

Mobilization of Normal Mouse Progenitors and Acute Promyelocytic Leukemia (APL) Cells with Inhibitors of CXCR4 and VLA-4 in Splenectomized and Unsplenectomized Mice.

M2-10B4 Mesenchymal Stromal Cells Confer an In Vitro Protective Effect of Murine mCGPR/+ Acute Promyelocytic Leukemic Cells Against Chemotherapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only